Misplaced Pages

Tofenacin

Clinical data
Trade names	Elamol, Tofacine, Tofalin
Other names	tofenacin hydrochloride (USAN US)
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name N-methyl-2-ethanamine
CAS Number	15301-93-6 10488-36-5 (HCl)
PubChem CID	25315
ChemSpider	23647
UNII	C4A112M10H
CompTox Dashboard (EPA)	DTXSID50864578
ECHA InfoCard	100.035.746
Chemical and physical data
Formula	C17H21NO
Molar mass	255.361 g·mol
3D model (JSmol)	Interactive image
SMILES O(CCNC)C(c1ccccc1)c2ccccc2C
InChI InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)17(19-13-12-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3 Key:PNYKGCPSFKLFKA-UHFFFAOYSA-N

Tofenacin is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of Astellas Pharma). It acts as a serotonin-norepinephrine reuptake inhibitor, and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. Tofenacin is also the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients.

See also

• Clemastine
• Orphenadrine
• Tiazesim

References

1. Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 1041. ISBN 978-3-88763-075-1. Retrieved 19 May 2012.
2. Buckingham J (1996). Dictionary of organic compounds: Chemical Abstracts Service registry number index. CRC Press. p. 6074. ISBN 978-0-412-54090-5. Retrieved 19 May 2012.
3. Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. 2013-01-15. p. 3268. ISBN 978-0-8155-1526-5. Retrieved 19 May 2012.
4. van Dijk J, Hartog J, Hillen FC (1 January 1978). "Non-Tricyclic Antidepressants". In Ellis GP, West GB (eds.). Progress in Medicinal Chemistry. Elsevier. p. 284. ISBN 978-0-7204-0655-9. Retrieved 19 May 2012.
5. Capstick N, Pudney H (1976). "A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy". The Journal of International Medical Research. 4 (6): 435–440. doi:10.1177/030006057600400610. PMID 800383. S2CID 40083513.
6. Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V (November 1989). "Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine". Pharmacopsychiatry. 22 (6): 246–249. doi:10.1055/s-2007-1014608. PMID 2616635. S2CID 39693625.

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Abandoned drugs
• Amines
• Astellas Pharma
• Antidepressants
• Ethers
• Muscarinic antagonists
• Serotonin–norepinephrine reuptake inhibitors
• 2-Tolyl compounds
• Nervous system drug stubs